BOULDER, Colo., Dec. 20, 2018 /PRNewswire/ -- Array
BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief
Executive Officer, Ron Squarer, will
speak at the 37th Annual J.P. Morgan Healthcare
Conference in San Francisco. The
public is welcome to participate in the conference through a
webcast on the Array BioPharma website.
Event:
|
37th
Annual J.P. Morgan Healthcare Conference
|
Presenter:
|
Ron Squarer, Chief
Executive Officer, Array BioPharma
|
Date:
|
Monday, January 7,
2019
|
Time:
|
11:30 a.m. Pacific
Time
|
Presentation
Webcast:
|
https://jpmorgan.metameetings.net/events/healthcare19/sessions/24031-array-biopharma-inc/webcast
|
Breakout
Webcast:
|
https://jpmorgan.metameetings.net/events/healthcare19/sessions/24357-array-biopharma-inc-q-a/webcast
|
About Array BioPharma
Array BioPharma Inc. is
a fully-integrated, biopharmaceutical company focused on
the discovery, development and commercialization of transformative
and well-tolerated targeted small molecule drugs to treat patients
afflicted with cancer and other high-burden
diseases. Array markets in the
United States BRAFTOVI® (encorafenib) capsules in
combination with MEKTOVI® (binimetinib) tablets for
the treatment of patients with unresectable or metastatic melanoma
with a BRAFV600E or BRAFV600K
mutation. Array's lead clinical programs, encorafenib
and binimetinib, are being investigated in over 30 clinical
trials across a number of solid tumor indications, including a
Phase 3 trial in BRAF-mutant colorectal cancer. Array's
pipeline includes several additional programs being advanced by
Array or current license-holders, including the following
programs currently in registration trials: selumetinib (partnered
with AstraZeneca), LOXO-292 (partnered with Loxo Oncology),
ipatasertib (partnered with Genentech), tucatinib (partnered with
Seattle Genetics) and ARRY-797.
Vitrakvi® (larotrectinib, partnered with Loxo
Oncology) is approved in the United
States and Ganovo® (danoprevir, partnered with
Roche) is approved in China. For
more information on Array, please
visit www.arraybiopharma.com or follow @arraybiopharma on
Twitter and LinkedIn.
CONTACT:
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-300769032.html
SOURCE Array BioPharma Inc.